Results 141 to 150 of about 41,154 (301)

Efficacy and safety of 2–4 mg brexpiprazole in the management of schizophrenia: A systematic review and meta‐analysis

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
This graphical summary illustrates the efficacy and safety of brexpiprazole (2–4 mg) in patients with schizophrenia. The meta‐analysis demonstrates significant improvement in clinical outcomes, with reductions in Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression ‐ Severity scale (CGI‐S) scores, indicating better symptom ...
Sher Bano, Aashan Ahmad, Abdul Haseeb Mohammed, Ismailova Rushana Nurbekovna, Saja Saad, Noor Fatima, Muhammad Bilal Akbar, Zainab Salahuddin, Sadikun Nabi, Mohammad Mustafa Ababneh, Laiba Ajmal, Sidra Hariss, Hiba Manaf, Farah Saleh, Raouf Khan   +14 more
wiley   +1 more source

The importance of longitudinal evaluation using DAT‐SPECT in organophosphate‐induced toxic parkinsonism

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
We performed longitudinal evaluation using magnetic resonance imaging (MRI) and dopamine transporter single‐photon emission computed tomography (DAT‐SPECT) in a case of organophosphate‐induced toxic parkinsonism. Fluid‐attenuated inversion recovery (FLAIR) images showed bilateral striatal hyperintensity in the acute phase, followed by reduction of ...
Shuhei Nakao, Yoichiro Kogoh, Hideki Funahashi, Yusei Yanoma, Minako Azuma, Yasushi Ishida, Yoji Hirano   +6 more
wiley   +1 more source

Clinical dilemma of mood stabilizer augmentation in treatment‐resistant schizophrenia with residual phase: A case report of valproate‐associated hypoglycemia and cytopenia, and subsequent lithium response

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
Abstract Background Mood stabilizer augmentation is frequently used in treatment‐resistant schizophrenia despite limited guideline recommendations. Evidence for its efficacy and safety in the residual phase, however, remains insufficient. Case Presentation A 49‐year‐old Japanese woman with treatment‐resistant residual schizophrenia exhibited persistent
Yoshiki Kasagi, Naomichi Okamoto, Reiji Yoshimura   +2 more
wiley   +1 more source

What if I needed help? Population preferences for first-line mental health treatments in the post-COVID time. [PDF]

Front Psychiatry
Voderholzer U, Wuttke EP, Zisler EM, Baumeister A, Jelinek L.   +4 more
europepmc   +1 more source

Brivaracetam‐associated manic episode in a patient with bipolar disorder: A case report

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
A patient with Bipolar I disorder developed manic symptoms following the initiation of brivaracetam for focal epilepsy. Although brivaracetam is generally considered to have favorable psychiatric tolerability, this case highlights a potential risk of mood destabilization in patients with underlying bipolar disorder.
Mihoko Kawai, Jun Miyata, Kousuke Kanemoto   +2 more
wiley   +1 more source

In Memory of Dr. Klaus Miczek, a prolific scientist, generous scholar, and cherished colleague. [PDF]

Psychopharmacology (Berl)
Maguire J, Weera M.
europepmc   +1 more source

Characteristics of mental health needs following the 2024 Noto Peninsula Earthquake: Comparison with the 2016 Kumamoto Earthquake

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
Compared with the 2016 Kumamoto Earthquake, Disaster Psychiatric Assistance Team (DPAT)‐recorded consultations after the 2024 Noto Peninsula Earthquake were fewer but included a higher proportion of adults aged ≥65 years; significant between‐disaster differences were observed for depression, flashbacks, somatic symptoms, suicidal ideation, anger ...
Yoshifumi Takagi, Sho Takahashi, Tatsuhiko Kubo, Yasuhisa Fukuo, Sayaka Gomei, Chie Yaguchi, Tetsuaki Arai, Hirokazu Tachikawa   +7 more
wiley   +1 more source

Editorial: Case reports in psychopharmacology, volume IV. [PDF]

Front Psychiatry
Stuhec M, Di Ciano P.
europepmc   +1 more source

CAT‐Hokkaido: A tablet‐based assessment of cognitive impairment in schizophrenia

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
CAT‐Hokkaido is a brief tablet‐based cognitive assessment covering six neurocognitive domains relevant to schizophrenia. In patients with schizophrenia, it detected deficits in four of six tasks and showed significant correlations with corresponding MCCB measures, supporting its potential utility in assessing cognitive impairment.
Atsuhito Toyomaki, Hayato Watanabe, Ryo Sawagashira, Chiemi Kubota, Naoki Hashimoto, Takahiro A. Kato   +5 more
wiley   +1 more source

Clinical predictors of stimulant efficacy in adults with ADHD. [PDF]

Ther Adv Psychopharmacol
DiSalvo M, Biederman J, O'Connor H, Iorini M, Green A, Woodworth KY, Wozniak J, Joshi G, Gabrieli J, Uchida M.   +9 more
europepmc   +1 more source